Our Impact

“For some time, we’ve been developing an exciting new way to use this immunotherapy combination—and we are thrilled to now be able to offer the treatment to patients. The Phase I clinical trial wouldn’t be possible without Cycle for Survival support. Our deepest thanks to the participants and donors for their commitment to rare cancer research.”